➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Baxter
Express Scripts
Boehringer Ingelheim
Moodys
McKinsey

Last Updated: September 28, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for REL-1017

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug REL-1017?

REL-1017 is an investigational drug.

There have been 31 clinical trials for REL-1017. The most recent clinical trial was a Phase 3 trial, which was initiated on March 1st 2012.

The most common disease conditions in clinical trials are Lymphoma, Lymphoma, B-Cell, and Lymphoma, Large B-Cell, Diffuse. The leading clinical trial sponsors are Merck Sharp & Dohme Corp., National Cancer Institute (NCI), and Relmada Therapeutics, Inc.

There is one US patent protecting this investigational drug and eleven international patents.

Recent Clinical Trials for REL-1017
TitleSponsorPhase
A Study to Assess the Rel Bioavailability, Food Effect and Absolute Bioavailability on the Pharmacokinetics of AZD9833Quotient SciencesPhase 1
A Study to Assess the Rel Bioavailability, Food Effect and Absolute Bioavailability on the Pharmacokinetics of AZD9833AstraZenecaPhase 1
An Extension Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic CancerBausch Health Americas, Inc.Phase 3

See all REL-1017 clinical trials

Clinical Trial Summary for REL-1017

Top disease conditions for REL-1017
Top clinical trial sponsors for REL-1017

See all REL-1017 clinical trials

US Patents for REL-1017

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
REL-1017   Start Trial Therapeutic approaches for treating Parkinson's disease Pharnext (Issy les Moulineaux, FR)   Start Trial
REL-1017   Start Trial Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer Capella Therapeutics, Inc. (San Diego, CA)   Start Trial
REL-1017   Start Trial Therapeutic approaches for treating Parkinson's disease PHARNEXT (Issy les Moulineaux, FR)   Start Trial
REL-1017   Start Trial Antibiotic compositions and methods of use University of South Florida (Tampa, FL)   Start Trial
REL-1017   Start Trial Composition comprising antifungal agents for treating vulvovaginitis and vaginosis Two Lines Co., Ltd. (Gwangju, KR)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for REL-1017

Drugname Country Document Number Estimated Expiration Related US Patent
REL-1017 Australia 2012222348 2031-03-01   Start Trial
REL-1017 Australia 2012222351 2031-03-01   Start Trial
REL-1017 Australia 2013224959 2031-03-01   Start Trial
REL-1017 Australia 2013224960 2031-03-01   Start Trial
REL-1017 Australia 2014314055 2031-03-01   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Baxter
Express Scripts
Boehringer Ingelheim
Moodys
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.